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of acute STEMI and bifurcation lesions. All patients were scheduled to undergo
angiographic follow-up at 6 months. The primary endpoint of the study was the
survival-free of MACE (cardiac death, MI and TLR) at 30 days. Secondary endpoints
included 6-month in-stent late lumen loss and binary restenosis.
Results: A total of 46 patients were enrolled with mean age of 63 years old, 76.6% of
male and 21.3% of diabetics. Mean RVD and lesion length were 3.03mm and
12.67mm, respectively. The Acrobat stent was deployed in 100% of the cases (89.6%
of DS) achieving a procedure success rate of 97.8%. Up to 30 days there was no
MACE. Six-month invasive follow-up was so far completed for 42 patients, with an
in-stent late loss of 0.76mm and only 3 cases of ischemia-driven TLR (7.6%). Complete
follow-up data will be available at the meeting.
Conclusion: The Acrobat SOAW may potentially facilitate PCI by reducing time/cost
and minimizing peri-procedural complications. The present trial represents the first-
in-man assessment of this innovative concept.
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Background: Long coronary lesions are associated with high restenosis rates and
adverse clinical outcomes. The platinum chromium PROMUS Element everolimus-
eluting stent (EES, Boston Scientific, Natick, MA) demonstrated noninferior clinical
outcomes compared to the XIENCE V EES (Abbott, Santa Clara, CA) in lesions
≤24mm. The PLATINUM Long Lesion (LL) study assessed results in lesions >24mm.
Methods: Patients had angina pectoris or documented silent ischemia. One de novo
target lesion >24 to ≤34mm long with reference diameter ≥2.50 to ≤4.25mm could be
treated with a 32 or 38mm stent. A lesion in a different epicardial vessel could be treated
with a non-study treatment before the target lesion. The primary endpoint, 12-month
target lesion failure (composite of target vessel related cardiac death/MI and ischemia-
driven target lesion revascularization) in the per-protocol population, was compared
to a performance goal (PG) of 19.4% based on historical outcomes with 32mm
paclitaxel-eluting stents (the only long drug-eluting stent approved in the US when
PLATINUM LL was initiated) in the TAXUS V DN trial. Clinical follow-up is at 1, 6,
12, 18M and annually to 5 years.
Results: 102 patients enrolled at 30 international sites. Table 1 shows baseline
characteristics and outcomes. TLF in the per-protocol population was 3.2% with a one-
sided upper confidence bound of 7.96%, significantly less than the PG (p<0.0001).
Conclusion: The PLATINUM LL results support the safety and efficacy of the 32 and
38mm PROMUS Element stent.
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Background: Durable polymers used for first-generation drug-eluting stents
potentially contribute to persistent inflammation, delayed endothelial healing, and late
stent thrombosis. NOYA is a Co-Cr based sirolimus-eluting stent (SES) with DL-
Polylactide biodegradable polymer (Medfavour Medical, Beijing, China). The present
study aimed to evaluate the efficacy and safety of NOYA stent in treating de novo
coronary artery lesions.
Methods: NOYA I trial was designed to test the non-inferiority of in-stent late loss of
NOYA stent compared to FIREBIRD 2 stent, a widely used SES with durable polymer
in China (MicroPort Medical, Shanghai, China). Subjects with maximum of two de
novo native coronary lesions with DS% >= 70% by visual estimation (Age 18-75,
lesion length <= 30mm, RVD 2.5-4.0mm) were enrolled. The primary endpoint was
in-stent late loss at 9-month. The secondary endpoints were binary restenosis rates at
9-month, major adverse cardiac events (MACE) defined as the composite of cardiac
death, myocardial infarction (MI), or target lesion revascularization (TLR), and
definite/probable stent thrombosis at 12-month.
Results: A total of 300 patients (n=150 in each group) were enrolled from 16 Chinese
centers in the study. Baseline data and procedural results were comparable between
the two groups. The 9-month angiographic follow-up rate was 87.9%. In-stent late loss
was 0.11±0.20mm in NOYA vs. 0.13±0.19mm in FIREBIRD 2 group (non-inferiority
p=0.00000017). In-segment binary restenosis rates were similar in both groups (4.2%
vs. 3.7%, p=0.8028). The rates of MACE, TLR and MI at 12-month were same (4.7%
vs. 4.7%; 2.0% vs. 2.0%; 2.7% vs. 2.7%; respectively). Neither stent thrombosis nor
cardiac death was observed at 12-month.
Conclusion: The primary non-inferiority endpoint of in-stent late loss at 9-month was
met. Longer term follow-up and large scale trial are needed to further evaluate the
newly developed NOYA SES with biodegradable polymer coating. (clinicaltrials.gov
identifier: 01226355)
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Background: Durable polymers used for first-generation drug-eluting stents
potentially contribute to persistent inflammation and late DES thrombosis. We report
the first in human experience with the rapamycin-eluting biodegradable polymer coated
cobalt-chromium FIREHAWK (MicroPort Medical, Shanghai, China) stent with
abluminal groove.
Methods: Patients with stable or unstable angina, or prior myocardial infarction (MI),
with single de novo native coronary stenosis < 30mm in length in vessel sizes ranging
from 2.25 to 4.0 mm were enrolled at a single institution. The primary endpoint was
major adverse cardiac events (MACE) at 30-day defined as the composite of cardiac
death, MI (Q and non-Q), or ischemia-driven target lesion revascularization. Secondary
endpoints include 4 and 13 months in-stent late lumen loss by quantitative coronary
angiography, proportion of uncovered or malapposed stent struts by Optical Coherence
Tomography (OCT) at 4-month, and MACE at 4, 12, 24 and 36-month follow-up.
Results: A total of 21 patients (age 56.2±8.9 years, male 66.7%, diabetes 14.3%) were
enrolled consecutively in 1 month. The average baseline reference vessel diameter is
2.88±0.51 mm and the lesion length is 17.7±6.1 mm. There was no MACE at 30-day.
One patient died of non-cardiac hemorrhagic stroke 5 days after index procedure. 19
patients at 4-month and 14 patients at 13-month underwent angiographic follow-up,
respectively. The in-stent late loss was 0.13±0.18 mm at 4-month, and 0.16±0.07 mm
at 13-month. There was no binary restenosis. The complete strut coverage was 96.2%
by OCT with only 0.1% strut malapposition at 4-month among 11551 analyzed struts.
There was no MACE at 12-month.
Conclusion: The preliminary feasibility and safety of FIREHAWK stent are
demonstrated in the first in human study. OCT findings indicated excellent stent strut
coverage 4 months after implant. Further pivotal randomized trial will confirm if this
early results could translate into longer term safety and efficacy benefits.
B65JACC Vol 58/20/Suppl B  |  November 7-11, 2011  |  TCT Abstracts/POSTER/Bioabsorbable, Drug-Eluting, and Bare Metal Stent Studies
P
O
S
T
E
R
S
www.JACC.TCTAbstracts2011
